[Betaserk in the treatment of aftereffects of craniocerebral injury and vascular events].
Odinak
M M
MM
Kovalenko
A P
AP
D000208:Acute Disease; D000328:Adult; D001621:Betahistine / Q000008:administration & dosage / Q000627:therapeutic use*; D001921:Brain / Q000098:blood supply*; D001930:Brain Injuries / Q000150:complications*; D002545:Brain Ischemia / Q000188:drug therapy* / Q000209:etiology*; D002560:Cerebrovascular Circulation / Q000502:physiology; D004244:Dizziness / Q000188:drug therapy* / Q000209:etiology*; D004334:Drug Administration Schedule; D005260:Female; D006261:Headache / Q000188:drug therapy* / Q000209:etiology*; D017442:Histamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D017442:Histamine Agonists; D014665:Vasodilator Agents; D001621:Betahistine